NCYTE Trademark

Trademark Overview

On Monday, September 12, 2022, a trademark application was filed for NCYTE with the United States Patent and Trademark Office. The USPTO has given the NCYTE trademark a serial number of 97588036. The federal status of this trademark filing is EX PARTE APPEAL PENDING as of Friday, June 7, 2024. This trademark is owned by Ncardia B.V.. The NCYTE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pre-clinical scientific research and trials for others in the nature of creating human cell models from stem cells for use in drug efficacy testing in the field of biomedical research, none of the foregoing for the treatment of viral, hematological, oncological, auto-immune, inflammatory, metabolic, and dermatological disorders
ncyte

General Information

Serial Number97588036
Word MarkNCYTE
Filing DateMonday, September 12, 2022
Status760 - EX PARTE APPEAL PENDING
Status DateFriday, June 7, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPre-clinical scientific research and trials for others in the nature of creating human cell models from stem cells for use in drug efficacy testing in the field of biomedical research, none of the foregoing for the treatment of viral, hematological, oncological, auto-immune, inflammatory, metabolic, and dermatological disorders

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, September 28, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNcardia B.V.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLEIDEN 2333BD
NL

Trademark Events

Event DateEvent Description
Thursday, September 15, 2022NEW APPLICATION ENTERED
Wednesday, September 28, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 19, 2022ASSIGNED TO EXAMINER
Friday, January 6, 2023NON-FINAL ACTION WRITTEN
Friday, January 6, 2023NON-FINAL ACTION E-MAILED
Friday, January 6, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, April 6, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 6, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 6, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 12, 2023FINAL REFUSAL WRITTEN
Friday, May 12, 2023FINAL REFUSAL E-MAILED
Friday, May 12, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, August 14, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, August 14, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, November 13, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, November 13, 2023EXPARTE APPEAL RECEIVED AT TTAB
Monday, November 13, 2023EX PARTE APPEAL-INSTITUTED
Monday, November 13, 2023JURISDICTION RESTORED TO EXAMINING ATTORNEY
Tuesday, March 5, 2024ASSIGNED TO LIE
Tuesday, March 5, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 5, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 5, 2024SUBSEQUENT FINAL REFUSAL WRITTEN
Tuesday, March 5, 2024SUBSEQUENT FINAL EMAILED
Tuesday, March 5, 2024NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Tuesday, May 7, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, April 8, 2024NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Monday, April 8, 2024SUBSEQUENT FINAL REFUSAL WRITTEN
Monday, April 8, 2024SUBSEQUENT FINAL EMAILED
Tuesday, May 7, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 7, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 7, 2024ACTION CONTINUING FINAL - COMPLETED
Friday, June 7, 2024NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Friday, June 7, 2024ACTION DENYING REQ FOR RECON E-MAILED
Tuesday, August 20, 2024EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF

Related Keywords

ncyte research viral hematological treatment none biomedical oncological foregoing auto dermatological